

Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG

Leuven, Belgium, Boston, MA, US - March 17, 2022 – 07.00 PM CET – [Oxurion NV](#) (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian transparency legislation¹, it had received two transparency notifications following the closing of its private placement, which was announced on March 7, 2022.

Oxurion received a transparency notification dated March 14, 2022, from Fidelity Management & Research Company LLC, indicating that, by virtue of an acquisition of shares on March 7, 2022, through the private placement, it had acquired 3,128,819 common shares, which represents 6.7% of Oxurion’s voting rights, and thus crossed the 5% threshold (the “Fidelity Notification”).

Oxurion also received a transparency notification dated March 15, 2022, from Novartis Pharma AG and Novartis AG, which confirmed Novartis Pharma AG’s holding of 2,177,226 common shares, which as a result of the private placement now represents 4.7% of Oxurion’s voting rights, and thereby also crossed the 5% threshold (downwards) (the “Novartis Notification”).

Content of the Fidelity Notification

Reason of the notifications

Acquisition or disposal of voting securities or voting rights.

Notifications by

A parent undertaking or a controlling person.

Persons subject to the notification requirement

Name	Address (for legal entities)
FMR LLC	The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801.

Date on which the threshold is crossed

7 March 2022

¹ Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

Threshold that is crossed

5%

Denominator

46,628,892

Notified details

See Annex 1.

Chain of controlled undertakings through which the holding is effectively held

Fidelity Management & Research Company LLC is controlled by FMR LLC. FMR LLC is not a controlled entity.

Content of the Novartis Notification

Reason of the notifications

Passive crossing of a threshold.

Notifications by

A parent undertaking or a controlling person.

Persons subject to the notification requirement

Name	Address (for legal entities)
Novartis AG	Lichtstrasse 35, 4056 Basel, Switzerland
Novartis Pharma AG	Lichtstrasse 35, 4056 Basel, Switzerland

Date on which the threshold is crossed

7 March 2022

Threshold that is crossed

5%

Denominator

46,628,892

Notified details

See Annex 2.

Chain of controlled undertakings through which the holding is effectively held

Novartis Pharma AG is a wholly-owned direct subsidiary of Novartis AG.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the 40-50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-687 is a highly selective pan-RGD integrin antagonist that is being developed as a potential first line therapy for DME patients as well as wet AMD and potentially ME-RVO. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For more information, please contact:

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com</p> <p>Michaël Dillen Chief Business Officer Tel: +32 479 783 583 michael.dillen@oxurion.com</p>	<p><u>EU</u> <u>MEDiSTRAVA Consulting</u> David Dible/ Sylvie Berrebi/Frazer Hall Tel: +44 20 7638 9571 oxurion@medistrava.com</p> <p><u>US</u> <u>Westwicke, an ICR Company</u> Christopher Brinzey Tel: +1 617 835 9304 chris.brinzey@westwicke.com</p>
--	--

ANNEX 1

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
FMR LLC		0		0.00%	
Fidelity Management & Research Company LLC		3,128,819		6.71%	
Subtotal		3,128,819		6.71%	
TOTAL		3,128,819	0	6.71%	0.00%

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL					0	0.00%	

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	3,128,819	6.71%

ANNEX 2

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
	Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
Holders of voting rights					
Novartis AG	0	0		0.00%	
Novartis Pharma AG	2,177,226	2,177,226		4.67%	
Subtotal	2,177,226	2,177,226		4.67%	
TOTAL		2,177,226	0	4.67%	0.00%

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	2,177,226	4.67%



PRESS RELEASE
Regulated Information
March 17, 2022, 07.00 PM CET